Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 2/3 1

Status

Unknown 44Recruiting 37Completed 27Not yet recruiting 15Active not recruiting 10Withdrawn 7Terminated 4Enrolling by invitation 2Suspended 1

Sponsor Class

OTHER 7

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 7

Conditions

Carcinoma, Hepatocellular 7Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Sarcoma, Kaposi 1Hepatitis B 1GBM 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Advanced Hepatocellular Carcinoma 1Acrocephalosyndactylia 1

Interventions

Sorafenib 13Radiosurgery 9spartalizumab 7lenvatinib 7Oxaliplatin 6Gemcitabine 5Fluorouracil 5Radiotherapy 4Cisplatin 4Bevacizumab 4atezolizumab 3Leucovorin 3Folfox protocol 3Doxorubicin 3gadolinium ethoxybenzyl DTPA 2fludarabine 2cabozantinib 2Nivolumab 2Mitomycin 2Electroporation 2Cyclophosphamide 2Chemoembolization, Therapeutic 2tremelimumab 1toripalimab 1tocilizumab 1tislelizumab 1temsirolimus 1tazemetostat 1sitravatinib 1pirarubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Hepatocellular × lenvatinib × Clear all
NCT04044651 2020-01-09

Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection

Sun Yat-sen University

Phase 2/3 Withdrawn
Gastrointestinal

Hepatitis B, Carcinoma, Hepatocellular

NCT03919383 2019-06-03

Phase II of Lenvatinib Plus Toripalimab for Advanced HCC

Sun Yat-sen University

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03775707 2019-05-06

Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

Sun Yat-sen University

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03803254 2019-05-06

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Sun Yat-sen University

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03744247 2019-05-02

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Sun Yat-sen University

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03791918 2019-05-02

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Sun Yat-sen University

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03746249 2019-04-17

Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC

Sun Yat-sen University

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡